<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Travere Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/travere-therapeutics-inc</link>
<description>Latest news and press releases for Travere Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 20:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/travere-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ce3078dffbe2df11e58b.webp</url>
<title>Travere Therapeutics Inc</title>
<link>https://6ix.com/company/travere-therapeutics-inc</link>
</image>
<item>
<title>Travere Therapeutics to Report First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-to-report-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-to-report-first-quarter-2026-financial-results</guid>
<pubDate>Mon, 27 Apr 2026 20:30:00 GMT</pubDate>
<description>SAN DIEGO, April 27, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.</description>
</item>
<item>
<title>Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/ligand-partner-travere-therapeutics-receives-full-fda-approval-for-filsparir-sparsentan-in-fsgs-5</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/ligand-partner-travere-therapeutics-receives-full-fda-approval-for-filsparir-sparsentan-in-fsgs-5</guid>
<pubDate>Tue, 14 Apr 2026 11:00:00 GMT</pubDate>
<description>FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to reduce proteinuria in adult and pediat</description>
</item>
<item>
<title>Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-announces-full-fda-approval-of-filsparir-sparsentan-the-first-and-only-approved-medicine-for-fsgs</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-announces-full-fda-approval-of-filsparir-sparsentan-the-first-and-only-approved-medicine-for-fsgs</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndrome Additional indication for</description>
</item>
<item>
<title>Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 19 Feb 2026 21:01:00 GMT</pubDate>
<description>SAN DIEGO, February 19, 2026--Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update.</description>
</item>
<item>
<title>Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-report-fourth-quarter-213000732</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-report-fourth-quarter-213000732</guid>
<pubDate>Thu, 12 Feb 2026 21:30:00 GMT</pubDate>
<description>SAN DIEGO, February 12, 2026--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.</description>
</item>
<item>
<title>Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-present-guggenheim-emerging-213000926</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-present-guggenheim-emerging-213000926</guid>
<pubDate>Wed, 04 Feb 2026 21:30:00 GMT</pubDate>
<description>SAN DIEGO, February 04, 2026--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET.</description>
</item>
<item>
<title>Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-announces-fda-extends-182400728</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-announces-fda-extends-182400728</guid>
<pubDate>Tue, 13 Jan 2026 18:24:00 GMT</pubDate>
<description>SAN DIEGO, January 13, 2026--Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). The new Prescription Drug User Fee Act (PDUFA) target action date is April 13, 2026.</description>
</item>
<item>
<title>Travere Therapeutics Provides Corporate Update and 2026 Outlook</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-provides-corporate-update-and-2026-outlook-2026-01-12</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-provides-corporate-update-and-2026-outlook-2026-01-12</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>U.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025 Company positioned for successful</description>
</item>
<item>
<title>Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will</description>
</item>
<item>
<title>Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-1</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-1</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2021, the Compensation Committee of</description>
</item>
<item>
<title>Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-announces-late-breaking-data-phase-3-duplex-study-filspari-fsgs</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-announces-late-breaking-data-phase-3-duplex-study-filspari-fsgs</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>New late-breaking data from DUPLEX Study show significantly more FILSPARI® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g compared with</description>
</item>
<item>
<title>Travere Therapeutics to Participate at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-participate-upcoming-investor-conferences-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-participate-upcoming-investor-conferences-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming</description>
</item>
<item>
<title>Travere Therapeutics Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-reports-third-quarter-2025-financial-results-2025-10-30</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-reports-third-quarter-2025-financial-results-2025-10-30</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>U.S. net product sales of FILSPARI® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarter Total revenue</description>
</item>
<item>
<title>Travere Therapeutics to Report Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-report-third-quarter-2025-financial-results-2025-10-23</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-report-third-quarter-2025-financial-results-2025-10-23</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2025 financial results on Thursday,</description>
</item>
<item>
<title>Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-present-abstracts-american-society-nephrology-asn-kidney-week</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-present-abstracts-american-society-nephrology-asn-kidney-week</guid>
<pubDate>Fri, 17 Oct 2025 04:00:00 GMT</pubDate>
<description>Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line</description>
</item>
<item>
<title>CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/csl-vifor-and-travere-therapeutics-recognize-updated-kdigo-clinical-practice-0</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/csl-vifor-and-travere-therapeutics-recognize-updated-kdigo-clinical-practice-0</guid>
<pubDate>Fri, 26 Sep 2025 04:00:00 GMT</pubDate>
<description>FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss SAN DIEGO & ST. GALLEN,</description>
</item>
<item>
<title>Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-provides-update-fda-advisory-committee-meeting-filsparir</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-provides-update-fda-advisory-committee-meeting-filsparir</guid>
<pubDate>Wed, 10 Sep 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the</description>
</item>
<item>
<title>Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-presents-abstracts-15th-international-congress-inborn-errors</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-presents-abstracts-15th-international-congress-inborn-errors</guid>
<pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
<description>Presentation details long-term safety and efficacy data on pegtibatinase as a potential treatment for classical HCU SAN DIEGO--(BUSINESS WIRE)-- Travere</description>
</item>
<item>
<title>Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-announces-us-fda-approves-rems-modification-filsparir-sparsentan</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-announces-us-fda-approves-rems-modification-filsparir-sparsentan</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>FDA simplifies liver monitoring schedule from monthly to every three months for the duration of treatment and removes embryo-fetal toxicity REMS monitoring</description>
</item>
<item>
<title>Travere Therapeutics Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-reports-second-quarter-200100245</link>
<guid isPermaLink="true">https://6ix.com/company/travere-therapeutics-inc/news/travere-therapeutics-reports-second-quarter-200100245</guid>
<pubDate>Wed, 06 Aug 2025 20:01:00 GMT</pubDate>
<description>SAN DIEGO, August 06, 2025--Travere Therapeutics, Inc., (NASDAQ: TVTX) today reported its second quarter 2025 financial results and provided a corporate update.</description>
</item>
</channel>
</rss>